Irritable Bowel Syndrome News

Synergy Pharmaceuticals announced the FDA has approved Trulance for the treatment of constipation-predominant irritable bowel syndrome in adults.

Patients with irritable bowel syndrome who adhered to a low fermentable, oligo-, di-, mono-saccharides and polyol diet, known as the low FODMAPs diet, experienced improvement in gastrointestinal symptoms and quality of life, according to a new meta-analysis published in Nutrition.

Researchers observed a low rate of complete response to sorafenib treatment for hepatocellular carcinoma in a recent retrospective study; however, nearly all patients who achieved complete response also developed dermatologic adverse events, which may provide a correlation between toxicity and treatment response.

Tenapanor showed positive results in a safety extension study, which the manufacturer Ardelyx said will support a new drug application along with two successful phase 3 trials for constipation-predominant irritable bowel syndrome, according to a press release.

NEW YORK — In this exclusive video, Jack Braha, DO, a practitioner at Brooklyn Gastroenterology and Endoscopy, discusses how physicians can make “the conversation about poop” easier for patients with irritable bowel syndrome.

NEW YORK — In this exclusive video, Aimee Lenar, Allergan’s Vice President of GI Marketing, discusses the importance of educating clinicians, particularly primary care physicians, on the importance of early diagnosis for improving outcomes for the nearly 60 million Americans with irritable bowel syndrome or chronic idiopathic constipation.

Irritable bowel syndrome is a common gastrointestinal condition, affecting approximately 30 million people in the United States. The hallmark of this condition is change in bowel movements, such as diarrhea, constipation or slow-moving stools. Other symptoms include abdominal pain and cramping, fatigue and more. IBS can be treated by diet or lifestyle changes, medications, or probiotics.

Both low FODMAP diet and general dietary advice offered improved gastrointestinal symptoms at 6 weeks in patients with irritable bowel syndrome with diarrhea, though low FODMAP diet demonstrated greater symptom-relieving benefits. Quality of life between the groups saw similar decline, researchers reported.

Life science technology company IQuity announced the launch of IsolateIBS-IBD, a blood test that can diagnose inflammatory bowel disease and irritable bowel syndrome by analyzing RNA expression data.

ORLANDO — In this exclusive video from the World Congress of Gastroenterology at ACG 2017, Eamonn M.M. Quigley, MD, MACG, professor of medicine at Weill Cornell Medical College, and chief of gastroenterology and hepatology at Houston Methodist Hospital, discusses survey results from the BURDEN IBS-C Study, which showed constipation-predominant irritable bowel syndrome has a significant burden on patients, and that patients and health care providers alike find available treatments unsatisfactory.